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Abstract 
Cancer is a heritable disorder of somatic cells: environment and heredity are both important in the carcinogenic 
process. The primal force is the “two hits” of Knudson’s hypothesis, which has proved true for many tumours, 
including renal cell carcinoma. Knudson et al. [1, 2] recognised that familial forms of cancer might hold the key 
to the identification of important regulatory elements known as tumour-suppressor genes. Their observations 
(i.e., that retinoblastoma tend to be multifocal in familial cases and unifocal in sporadic presentation) led them to 
propose a two-hit theory of carcinogenesis. Furthermore, Knudson postulated that patients with the familial form 
of the cancer would be born with one mutant allele and that all cells in that organ or tissue would be at risk, 
accounting for early onset and the multifocal nature of the disease. In contrast, sporadic tumours would develop 
only if a mutation occurred in both alleles within the same cell, and, as each event would be expected to occur 
with low frequency, most tumours would develop late in life and in a unifocal manner [3, 4]. The kidney is 
affected in a variety of inherited cancer syndromes. For most of them, both the oncogene/tumour-suppressor 
gene involved and the respective germline mutations have been identified. Each of the inherited syndromes 
predisposes to distinct types of renal carcinoma. Families with hereditary predisposition to cancer continue to 
provide a unique opportunity for the identification and characterisation of genes involved in carcinogenesis. A 
surprising number of genetic syndromes predispose to the development of renal cell carcinoma, and genes 
associated with five of these syndromes have been already identified: VHL, MET, FH, BHD and HRPT2. Few 
cancers have as many different types of genetic predisposition as renal cancer, although to date only a small 
proportion of renal cell cancers can be explained by genetic predisposition. 
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Plasticity of kidney cells 
The progression of renal stem cells to carcinogenic events and the associated loss of function 
remain one of the main challenges in kidney cancer. Both glomerular and tubular epithelial cells 
regress to primitive/embryonic mesenchymal phenotype in response to injury through the trans/de-
differentiation phenomenon. The phenotypic changes affecting renal cells have been labelled trans-
differentiation. The term “trans-differentiation” is probably misleading, as it refers to the 
transformation of one mature, epithelial phenotype into another. The phenotypic changes observed, 
involving mesangial and epithelial cells, are more likely to represent a step of injury-induced de-
differentiation/regression of these cells into a mesenchymal, embryonic phenotype reminiscent of the 
metanephric phenotype from which they originate [5]. On the other hand, these events have been 
described as epithelial mesenchymal transition.  
 
This reverse embryogenesis can be a key step in renal carcinogenesis. In fact, the response to 
injury of differentiated renal cells is, in some ways, a form of reverse embryogenesis (de-
differentiation) followed by a recapitulated embryogenesis (re-differentiation) leading to the 
restoration of kidney cell maturity. In addition to the plasticity of intrinsic renal cells, it is becoming 
apparent that renal remodelling in health and disease involves the migration of progenitor 
haematopoietic stem cells into the kidneys. These cells assume various glomerular and tubular 
epithelial phenotypes.  
 
Special mention focuses on the prospective contributions to the renal healing deviation of resident 
renal cells and those derived from the bone marrow and their circulating progeny.  
Plasticity of glomerular cells  
Endothelial cells  
Experimental data suggest that the response of glomerular cells to injury is more complex, 
involving considerable phenotypic adaptation. For instance, endothelial cells, once injured 
transiently, lose their mature functional phenotype (i.e., anticoagulant, anti-inflammatory, 
antiproliferative) and acquire new immature (i.e., procoagulant, proinflammatory and mitogenic) 
characteristics [6].  
Mesangial cells  
The phenotypic changes of mesangial cells in response to injury have been demonstrated. 
Mesangial cells trans- or de-differentiate in response to injury, from a mature, adult, pericyte-like 
phenotype (the mesangiocyte) to an embryonic myofibroblastic one (the mesangioblast), 
characterised by proliferation and contraction [7, 8]. The appearance of mesangioblasts within 
glomeruli undergoing repair appears to re-enact the embryonic steps of glomerulogenesis [9–11]. To 
sum up, the trans/de-differentiation of adult mesangial cells (mesangiocytes) to embryonic mesan- 
gioblasts is characteristic of mesangial response to injury.   
Epithelial cells  
Glomerular parietal epithelial cells also respond to injury by trans/de-differentiation into a 
mesenchymal–embryonic phenotype, which is associated with the loss of tubulo-epithelial markers 
[12]. At the early and later stages of glomerular epithelial–mesenchymal trans-differentiation, 
epithelial cells retain their morphology [13].  
  
Plasticity of tubulointerstitial cells  
Tubular epithelial cells have the capacity to regress from an adult, mature phenotype to an 
embryonic/mesenchymal one in response to injurious stimuli. This so-called epithelial–mesenchymal 
trans-differentiation, or rather, transformation, has been reported in response to a variety of stimuli 
and appears to be mediated by the release of a variety of growth factors (TGF-β1, EGF) and 
cytokines (IL-1) in vitro and in vivo, where the proximal tubular epithelial cells lose their adult 
phenotype and markers and acquire mesenchymal ones [13–15].  
 
Epithelial–mesenchymal transition is associated with the loss of epithelial phenotype involving 
cell hypertrophy [14]. This so-called epithelial–mesenchymal transition is merely the regression of 
the adult phenotype to the tubular epithelial cell’s embryonic/metanephric mesenchymal one in 
response to injury. As the great majority of tubular epithelial cells, including proximal tubular cells, 
are derived from the same metanephric mesenchyme, these cells can regress to such an embryonic 
mesenchymal phenotype in response to activation.  
The contribution of haematopoietic stem cells  
Bone marrow has multiple types of stem cells (Fig. 1) (haematopoietic stem cells, mesenchymal 
stem cells, multipotent adult progenitor cells, side population cells) and numerous studies have 
reported differentiation when these cells engraft in other organ systems.  
 
 
 
Fig. 1. Theoretical work of bone marrow. Bone marrow stem cells derive into three major populations: MSC, HSC and BMLC. 
These three populations could give rise to an intermediate stage, MC/fibroblast. Finally, MC/fibroblast could trans-differentiate 
to AC, IF, Mes C, GEC and TEC. Abbreviations: MSC, marrow stromal cell; HSC, hematopoietic stem cell; BMLC, bone 
marrow lining cell; MC, mesenchymal cell; AC, adventitial cell (pericyte); TEC, tubuloepithelial cell (proximal tubules cell); 
IF, interstitial renal fibroblast; MesC, mesangial cell; GEC, glomerular epithelial cell                            
The pluripotency of haematopoietic stem cells is evidenced by their capacity to differentiate into 
multiple lineages within the blood and immune system, as well as non-cross lineage boundaries to 
become cells of other tissues, which has challenged the traditional view that somatic stem cells are 
lineage-restricted and organ-specific. One possibility is that some haematopoietic stem cells retain 
developmental plasticity and can be programmed to express genes that are required to differentiate 
into the cells of the organs into which they are introduced.  
 
Bone marrow has received increasing attention during recent years from researchers hoping to 
reveal a universal stem cell. There are two main reasons for this. Firstly, bone marrow has the 
capacity for pluripotent differentiation. And secondly, for an organ system in which a native stem- 
cell region has not yet been identified, such as the kidney, bone marrow may serve as an alternative 
source. Previous discoveries of blood-borne cells in the kidney, and the characterisation of a potential 
universal stem cell source, giving rise to intact kidney tissue, are challenging long- held views about 
the nature of the kidney epithelium and its power to renew.  
 
The ability of haematopoietic stem cells to adopt the cell fate of the organs in which they reside 
suggests that these primitive cells could potentially differentiate into kidney cells during kidney 
regeneration (Fig. 2). There are reports that provide evidence showing that adult bone-marrow-
derived haematopoietic stem cells integrate into injured kidneys and differentiate into many renal 
cells. It has been shown, in experimental models, that bone marrow-derived stem cells can engraft in 
the kidney and differentiate into mature tubular epithelium, glomeruli and mesangium. Furthermore, 
resident kidney cells with features of marrow stem cell properties have been identified. 
 
 
 
Fig. 2. Plasticity of hematopoietic stem cells. Model of the possible biological explanations for mediate kidney epithelial 
engrafment. These include: a) trafficking of marrow cells to a local progenitor niche in the kidney, b) fusion of bone marrow-
derived cells with differentiated epithelial cells in the kidney, and c) direct “transdifferentiation” into kidney epithelial cells. 
PMC, pluripotent marrow cell,; HSC, hematopoietic stem cell; MSC, mesenchymal stem cell; MAPC, multipotent adult 
progenitor cell; KCP; kidney-committed progenitor  
Hereditary forms of renal carcinoma 
Renal cancer, like other human tumours (i.e., breast, colon and prostate cancers), occurs in a 
sporadic non-inherited form as well as an inherited or hereditary form (Table 1) [16]. Because there 
are a number of histological types of renal carcinoma, there are a number of hereditary types of renal 
carcinoma. Each type of hereditary renal carcinoma is associated with a specific histological type: (1) 
Von Hippel-Lindau (VHL) is a hereditary form of clear cell renal carcinoma; (2) hereditary papillary 
renal carcinoma (HPRC) is a hereditary form of papillary renal carcinoma (papillary type I); (3) Birt 
Hogg Dubé (BHD) is a hereditary form of chromophobe renal carcinoma and oncocytoma; or (4) 
human leiomyomatosis renal cell carcinoma (HLRCC) is a hereditary form of papillary renal 
carcinoma (papillary type 2) (Fig. 3).  
Table 1. Heritable syndromes associated with kidney neoplasias 
Syndrome Causative gene Renal manifestation 
Other manifestations (benign/malignant) 
location 
    
Von Hippel-Lindau (VHL) VHL, 
3p25 
Clear-cell RCC 
Solid/Cystic 
Multiple/Bilateral  
Retinal & CSN haemangioblastomas 
Pheochromocytomas. Neuroendocrine tumor 
Pancreatic cysts 
Endolymphatic-sac tumors 
Epididymal & broad-ligament cystadenomas 
Hereditary papillary  
Renal carcinoma (HPRC)  
MET, 7q31  Papillary RCC type 1  
Solid/Multiple/Bilateral 
None?  
Hereditary leiomyomatosis  
Renal carcinoma (HLRCC)  
FH, 1q42-43  Papillary RCC type 2  
Collecting duct 
carcinoma 
Solid/Aggressive 
Uterine leiomyoma & leiomyosarcomas  
Cutaneous nodules (leiomyomas) 
Birt Hogg Dubé (BHD) BHD, 17p11.2 Chromophobe RCC  
Hybrid oncocytoma RCC  
Oncocytoma  
Clear-cell RCC 
Multiple/Bilateral 
Cutaneous papules (fibrofolliculomas) 
Lung cysts. Spontaneous pneumothorax 
Possibly colon polyps 
Hyperparathyroidism-jaw HRPT2, 1q25-32 Mixed epithelial & 
stromal tumors  
Parathyroid tumor 
Tumor (HP-JT)   Papillary RCC  
Cysts 
Fibro-osseous mandibular & maxyllary 
tumours 
Constitutioned 
chromosome-3 
Translocation 
Unknown gene 
VHL? 
Clear-cell RCC 
Multiple/Bilateral  
None? 
Familial papillary thyroid  
Cancer (FPTC)  
Unknown gene  
1q21  
Papillary RCC  
Oncocytoma  
Papillary thyroid cancer 
Nodular thyroid disease 
    
 
  
 
 
 
Fig. 3. Kidney cancer is not a single cancer. There are different types of cancer that occur in kidney. These different types of 
kidney cancer are caused by different genes, they have diverse clinical courses and may respond differently to therapy 
Kidney cancer can occur in sporadic as well as hereditary forms. Sporadic kidney cancer tends to 
occur as a single lesion; inherited forms of kidney cancer can be bilateral and multifocal. The 
hallmarks of familial renal cancer are that they occur at an early age, and are usually bilateral and 
multifocal. The type about which most studies are available is associated with VHL disease, in which 
40–45% of affected individuals have clear cell carcinoma [17, 18]. Clear cell renal cancer is also 
inherited in about 50% of patients [19, 20] with the germline translocations. HPRC is a form of 
familial cancer that also has autosomal dominant trans- mission but reduced penetrance compared to 
VHL and familial cell cancer [21, 22]. Hereditary renal oncocytoma is a form of inherited renal 
tumour [23].  
  
Hereditary clear cell renal carcinoma  
Patients with VHL disease, caused by a germline mutation in the VHL gene (chromosome 3p25), 
have conventional renal cancer as part of an inherited tumour syndrome [24, 25]. Families with a rare 
hereditary form of conventional renal cancer have germline translocations involving chromosomes 3, 
t(3;8), t(3;6) and t(3;2) [26, 27]. The VHL kidney cancer gene is a tumour-suppressor gene. In VHL 
tumours the inherited (germline) copy of VHL is mutated, and the second copy of VHL gene is also 
inactivated, most often by deletion of the gene (Fig. 4). VHL mutations result in carcinogenesis. 
Tumorigenesis may be related, at least in part, to biochemical processes dependent on inter- action 
with transcriptional factor proteins referred to as hypoxia-inducible factors (HIF) 1α and 2α. HIF1α 
and HIF2α are key proteins involved in oxygen sensation. As a result, HIF1α and HIF2α are able to 
activate the transcription of a variety of genes that may be important for carcinogenesis, including: 
vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), transforming 
growth factorα (TGFα), glucose transporter-1 (Glut-1) and erythropoietin (EPO).  
 
 
 
Fig. 4. VHL mutations and kidney carcinogenesis. Tumorigenesis may be related, at least in part, to biochemical processes 
dependent on interaction with transcriptional factor proteins referred to as hypoxia-inducible factors (HIF) 1α and 2α. HIF1α 
and HIF2α are key proteins involved in oxygen sensation  
Hereditary papillary renal carcinoma type 1  
The hereditary papillary renal cell carcinoma gene is the protooncogene c-MET, which was found 
to be located at chromosome 7q31.1-34 (Fig. 4). Missense mutations were found in the tyrosine 
kinase domain of the MET gene in the germline of affected members of HPRC kindreds [28]. 
Mutations in the MET genes were also found to be located in codons that were homologous to those 
in the c-kit and RET oncogenes. The findings suggested that the missense mutations located in the 
MET proto-oncogene lead to constitutive activation of the MET protein in papillary renal carcinomas 
(Fig. 5). c-MET codes for the cell surface receptor for hepatocyte growth factor (HGF). Activation of 
c- MET by its ligand, HGF, activates the tyrosine kinase activity of c-MET that initiates multiple 
signal transduction cascades, resulting in cellular processes, including mitogenesis, migration and 
morphogenesis, which may be carcinogenic when unregulated.  
 
 
 
Fig. 5. HPRC cell with Met mutation. Met is a cell surface receptor for ligand HGF. Met gene mutation in germline of affected 
individuals with HPRC is associated with bilateral, multifocal type 1 papillary renal carcinoma 
Hereditary chromophobe/oncocytoma: BHD syndrome   
Kidney cancer may develop in 15–30% of affected BHD cases. The cancers are often bilateral and 
multifocal, and the most common types of histological types of renal tumour in this syndrome are 
chromophobe renal carcinoma (34%), oncocytic-transition neoplasms (50%) and oncocytoma (5%). 
Genetic linkage analysis was performed and the BHD gene was localised on the short arm of chromo- 
some 17 [29]. Mutations of the BHD gene were found in the germline of affected individuals with 
this syndrome. This gene has characteristics consistent with a tumour-sup- pressor gene [30]. BHD 
represents a genetic syndrome not linked to the VHL or c-MET genes.  
  
Hereditary papillary renal carcinoma type 2  
HLRCC is a hereditary form of papillary renal carcinoma type 2 and represents a disease complex 
characterised by the appearance of multiple tumours [31, 32]. The gene for HLRCC was found to be 
the gene that codes for fumarate hydratase (FH), a Krebs cycle enzyme (Fig. 6). FH catalyses the 
hydration of fumarate to form malate. FH acts as a tumour-suppressor gene, but the exact mechanism 
for tumorigenesis in HLRC remains to be elucidated. It is known that fumarate, which may 
accumulate in the setting of depressed FH activity, can prevent HIF hydroxylation by inhibiting 
prolyl hydroxylase. In the setting of loss of FH activity, fumarate accumulation may cause HIF 
overexpression and thereby result in a cellular milieu conducive to tumour formation.  
 
 
 
Fig. 6. Fumarate hydratase pathway implicated in human leiomyomatosis renal cell carcinoma 
  
Genetics of renal neoplasms  
Clear cell carcinoma  
Clear cell carcinoma occurs in both familial and sporadic forms, and in both forms it is 
characterised by the loss of VHL tumour-suppressor gene. The familial form of the common clear 
cell variant of renal cell carcinoma is VHL disease. This relatively rare disease is estimated to affect 
approximately 1 in every 36,000 individuals and is inherited in an autosomal dominant fashion with 
estimated penetrance of 80–90% by the age of 65 [33, 34]. Renal cell carcinoma eventually develops 
in approximately 35–45% of those individuals affected with VHL disease [35]. Early clues to the 
genetic elements involved in the development of renal cell carcinoma came to form cytogenetics. 
These studies demonstrated a common loss of chromosome 3 in kidney cancer, particularly the clear 
variants, and led to intensive efforts to find a tumour-suppressor gene in this region. Southern blot 
testing and analysis for restriction fragment length polymorphisms with a wide variety of genetic 
markers subsequently demonstrated loss of heterozygosity in distinct regions on the short arm of 
chromosome 3 [36]. Molecular linkage studies in patients with VHL disease eventually led to the 
identification of the VHL tumour-suppressor gene [37]. The VHL gene has been localised to the short 
arm of chromosome 3, sub-band 25 (3p25) (Table 2) [38–40], and its role as a tumour-suppressor 
gene for both the sporadic and the familial forms of clear cell renal carcinoma has been confirmed. 
VHL was linked to the locus encoding the human homologue of the RAF1 oncogene map- ping to the 
3p25 chromosome [41] and also linkage to D3S18 (a polymorphic DNA marker) [41] and tight link- 
age to D3S601 (DNA probe), which was located in the region between RAF1 and D3S18 [42].  
Table 2. Classification schema for kidney epithelial neoplasias 
Histological type  Cell origin  Genes implicated  Chromosomal abnormalities 
    
Clear cell RCC  Proximal tubule  VHL, BHD  -3p, +5q, -Y, -9p, -14q  
t (3;5) (p;q) 
Papillary RCC  Proximal tubule  MET, FH, HRPT2  +7, +17, -Y, +12, +16, +20 
t(X ;1) (p11.2;q21.2) 
t(X;17) (p11.2;q25.3) 
Chromophobe RCC  Intercalated cell  
Cortical collecting duct  
BHD  -1, -2, -6, -10, -13, -17, -21 
Oncocytoma  Intercalated cell  
Cortical collecting duct  
BHD -1, -Y 
t(5;11) (q35;q13) 
t(9;11) (p23;q13) 
Bellini ́s duct Medullary collecting duct FH -7q32, -6p, -8p, -21q 
    
 
Several hundred germline mutations have now been recognised; these include microdeletions, 
insertions, large deletions and missense and nonsense mutations. There are mutations identified 
throughout the coding region, but clustering occurred at the 3' end of EXON 1 and the 5' end of 
EXON 3 with a paucity of mutations in EXON 2. The importance of this is that a specific mutation 
has now been correlated with certain phenotypic characteristics in VHL patients [43, 44].  
 
An additional genetic abnormality is that chromosomes 3 are often reported in clear cell 
carcinoma (Table 3).  
  
Table 3. Additional genetics abnormalities in clear cell carcinoma 
Others chromosome 3p abnormalities  HISTOLOGICAL & CLINICAL FEATURES 
     
LOH discrete regions  3p13-p14.2  
3p12-p21.1 
  (63, 64) 
Early genetic changes     
LOH VHL gene  TGFa/TGF-b1  
c-myc 
 dedifferentiation  
cellular control  
transformation 
(65) 
(66)  
(67) 
Late events     
Duplication  5q22-qter segment   progression  (68,69)  
Trisomy  5q   progression  (70)  
Mutation  17p13 high mutation  p53  sarcomatous profile  (71, 72)  
 Low mutation  p53  carcinomatous profile  (73, 74) 
LOH 17p    tumor grade  (75, 76)  
   nodal metastases  (77) 
Allelic loss  17p 8p 9p 11p    
 14q 13q   tumor progression  (78, 79)  
Hepatocyte growth factor    overexpression  (80-82) 
c-erbB-1 oncogene    overexpression  (83) 
HER 2/neu oncogene    low expression  (84) 
     
 
Papillary renal cell carcinoma  
There are two broad classifications of the tumour: sporadic and hereditary. The main cytogenetics 
abnormalities associated with chromophilic renal cell carcinoma are characteristic (Table 2) and 
include trisomy of chromosomes 7 and 17 and loss of the Y chromosome. Other common findings 
include gain of chromosomes 12, 16 and 20 and loss of heterozygosity on chromosome 14. Papillary 
renal cell carcinoma has not been associated with 3p mutations (as is found in clear cell carcinoma), 
confirming distinct genetic pathways to tumorigenesis. Instead, it is associated with the MET proto-
oncogene, found on chromosome 7 [45], which encodes the receptor for HGF [46]. This gene was 
localised to chromosome 7q31-34 and activation of the MET proto-oncogene is the inciting event, 
rather than inactivation of a tumour-suppressor gene. Oncogenic properties of the MET gene are 
related with amplifications and mutations that result in the activation of this encoded protein [47, 48]. 
The protein product of this gene is the receptor tyrosine kinase for the HGF (also known as “scatter 
factor”), which plays an important role in the normal organogenesis, proliferation and differentiation 
of epithelial and endothelial cells in a wide variety of organs, including the kidney.  
 
Sporadic papillary carcinoma of the kidney is associated with more than one chromosomal 
abnormality: 80% possess polysomies [49]; 80–90% have been associated with loss of their Y 
chromosome [50]; loss of heterozygosity is detected on chromosomes 9q, 11q, 14q, 21q and 6p [51]; 
somatic translocations of chromosomes 1 and X have been reported [52]. To sum up, the most 
common trisomies that have been observed include trisomy of chromosomes 7, 17 and 16 [46, 49, 
53].    
 
Hereditary papillary renal cell carcinoma is associated with abnormalities of chromosome 7 [54], 
especially the MET proto-oncogene [55]. The MET proto-oncogene has been localised to the 7q31.3 
region [56]. Trisomy for chromosome 7, which is commonly found in hereditary papillary renal cell 
carcinoma, develops primarily through du- plication of the chromosome harbouring the mutant allele 
of the MET proto-oncogene and increases the dosage of the activated receptor, and this non-random 
event also con- tributes to the development of the tumour diathesis [57]. The second type of 
hereditary papillary renal cell carcinoma (referred to as type 2) is an autosomal-dominant condition 
due to a mutation in the FH gene [56]. The FH gene maps to the 1q42.3-43 chromosome. It is 
believed that FH is an enzyme of the Krebs cycle and is a “housekeeping” gene.  
  
Chromophobe cell carcinoma  
Genetic analysis [57] has revealed loss of heterozygosity at chromosomes 1, 6, 10, 13, 17 and 21 
(Table 2); in most cases there is demonstrated hypodiploid DNA content [58].  
 
Chromophobic renal cell carcinoma is commonly seen in BHD syndrome [59], but is rare in 
sporadic renal tumours [57]. The BHD gene has been mapped to the 17p11.2 locus (Fig. 4) and is 
thought to be a tumour-suppressor gene [60]. Some studies have reported an increased incidence of 
p53 mutation in this histologic subtype, and upregulated expression of the c-kit oncogene has also 
been reported [61].  
Collecting duct (Bellini’s duct)  
Deletions on chromosome 1q (loss of heterozygosity at 1q32.1-32.2) and monosomies of 
chromosomes 6, 8, 11, 18, 21 and Y are reported [40] (Table 2).  
 
Collecting duct carcinomas are typically characterised by hypodiploid stem lines with 
chromosomes 1, X and Y most commonly affected [44]. Additional abnormalities have been found 
on chromosomes 22 and 23 [62].  
Pathological features  
Kidney cancer is not a single disease, but a number of different types of cancer that occur in the 
kidney, each with a different histological type, clinical course and caused by different genetic 
abnormalities. Carcinogenesis can be considered as resembling an opened fan because initiated cells 
grow on several planes, and clinical studies of tumours suggest the edge of the fan contains many 
gene abnormalities: initiated cells grow in many directions and culminate in diverse clinical cancer 
subtypes at the periphery. The edge of the fan corresponds to pathological features (Fig. 7).  
 
 
 
Fig. 7. Fan model of kidney epithelial carcinogenesis from stem cell niche. CCRCh/s, clear cell renal carcinoma 
[hereditary/sporadic]; PRCC-1/-2, papillary renal cell carcinoma [type 1/type 2]; ChCC, chromophobe cell carcinoma; Cd-CC, 
collecting duct cell carcinoma; MMSC, metanephric mesenchymal stem cell 
  
At the time the developing kidney first becomes an anatomical entity, it is made up of the 
metanephric mesenchyme and the invading ureteric bud. It has long been known that the cells of the 
ureteric bud are the precursors of the collecting duct epithelial cells; the metanephric mesenchyme 
contains precursors for the epithelial cells of the rest of the nephron, endothelial cells precursors and 
stromal cells. Given the principle that cancer must arise from a cell that has the potential to divide, 
and the cancer stem cell concept has arisen to describe cells that represent a minority population of a 
tumour, having the property of self- renewal, activated stem cells in the kidney would be the target 
cells for renal carcinogenesis. Inactivation of genes such as VHL, MET, FH or BHD would transform 
kidney tissue stem cells into hyperplastic lesions, the target for further events leading to the 
progression of premalignant cells to malignancy (Fig. 8).  
 
 
 
Fig. 8. Theoretical origin of different RCC types from metanephric mesenchymal stem cell through malignant differentiation 
induced by many mutations of specific genes 
All renal cell carcinomas are, by definition, adenocarcinomas derived from renal tubular epithelial 
cells. Most renal cell carcinomas share ultrastructural features with nor- mal proximal tubular cells 
and they are believed to be derived from this region of the nephron (Fig. 9). Immuno- histochemical 
observations indicate that the antigenic com- position of the nephron varies in different regions [85, 
86]. Antibodies to glycoproteins of various molecular weights can distinguish proximal from distal 
tubules and collecting ducts. Identification of these areas is not yet exact but may be helpful in 
determining the origin and differentiation of certain renal neoplasms [87, 88].  
  
 
 
 
Fig. 9. Summary diagram, showing cells from the various regions of the urinary tubule (normal and tumoral) 
Renal cell carcinomas were traditionally thought to arise primarily from renal tubular structures 
and this is probably true for most clear cell and papillary variants. Although common renal cell 
carcinoma and papillary renal cell carcinoma are both derived from the same part of the renal tubule 
and have similar antigenic phenotype, they differ in genetic changes. This might be explained by the 
fact that common renal cell carcinoma arises from mature renal tubular cells, whereas papillary 
tumours arise from embryonic origin rest; recent data suggest that the other histological subtypes are 
derived from the more distal components of the nephron.  
Clear cell carcinoma  
Clear cell carcinoma is the histopathological subtype that ac- counts for the majority of renal cell 
carcinomas, and occurs in both familial and sporadic forms. In both forms it is characterised by the 
loss of a tumour-suppressor gene, namely the VHL gene. It accounts for approximately 75% of all 
renal cell carcinomas. They are characterised by tumour cells with clear cytoplasm (lipid and 
glycogen accumulation) and an acinar growth pattern. This tumour has been a subject of intense 
interest and, though histogenesis remains controversial, is believed to emerge from the proximal 
tubule.  
 
Immunohistochemical studies indicate that the anti- genic composition of renal cell carcinomas is 
variable. These neoplasms manifest determinants common to renal tubules, but evidence suggests 
that they develop from an uncommitted or primitive cell (stem cell) [86]. Cells tend to react with 
antibodies to low- and high-molecular-weight cytokeratins and vimentin (Table 4) [89, 90].  
  
Table 4. Immunohistochemistry profiles of renal cell carcinomas 
Histology  
Architecture 
Antigen markers  Reference 
   
Clear cell  lmw cytokeratins CK8, CK18, CK19  (15, 16, 18-23)  
Solid/alveolar/acinar  AE1, Cam 5.2, Vimentin  
 hmw cytokeratins CK14, 34βE12  
 CD10, MUC1, MUC3  
Papillary  cytokeratin CK7, vimentin  (24, 25) 
 AE1/AE3 Cam 5.2, Callus  
 CD10, S100  
Chromophobe  pan cytokeratin+, vimentin –  (18, 21, 22) 
Solid/glandular  EMA +, Lectins +  (26) 
 Parvalbumin +, CD10  
Collecting duct  hmw keratins 34 E12, CK19  (27) 
Tubular/tubulopapillary  lmw keratins vimentin  
 CD15, EMA , CD10–  
   
 
Papillar carcinoma  
This is the second most common histologic malignant tumour of the kidney. It accounts for 
approximately 5–10% of renal cell carcinomas. It is an enigmatic group that includes at least two, and 
possibly three, distinct types: papillary, tubular or tubulo-papillary. Some tumours have a solid 
growth pattern and other tumours have a striking glomeruloid appearance. Grossly, the papillary type 
is well circumscribed and eccentrically situated in the renal cortex. Tumours of this subtype are found 
in the walls of cysts. Papillary tumours often exhibit abundant lipid-laden macro phages within the 
interstitium of the fibrovascular cores. They tend to be multifocal and with bilateral disease. 
Histologic development is common in acquired cystic disease and from proximal tubule.  
Chromophobe cell carcinoma  
This is a distinctive histological subtype representing 3–5% of all renal cell carcinomas. The 
morphological appearance includes a solid pavement or cobblestone growth pattern. It appears to be 
derived from the intercalated cells at the cortical portion of the collecting duct. Immunohisto- 
chemically, tumour cells react positively with antibodies to cytokeratins, epithelial membrane antigen 
and carbonic anhydrase C. They do not react to vimentin [91–93].  
Oncocytoma  
They constitute approximately 6–9% of renal cortical neo- plasms. They are characterised by 
tumour cells arranged in nest, cords or tubules but never exhibit a papillary growth pattern. A central, 
stellate scar has been considered to be characteristic of this type of tumour. It appears to be de- rived 
from the intercalated cells at the cortical portion of the collecting duct.  
Collecting duct (Bellini’s duct) carcinoma  
This is a relatively rare subtype of renal cell carcinoma, ac- counting for less than 1% of all renal 
cell carcinomas. Collecting duct carcinoma of the kidney, including Bellini tumours, is a rare 
histological type of renal cell carcinoma with distinctive clinical and histopathological features. Un- 
like the majority of renal cell carcinoma tumours, collecting duct carcinoma originates in the distal 
collecting ducts [94]. Generally, the tumour is often centrally located in or near the region of the renal 
pelvis. Collecting ducts near the tumour often show dysplastic changes.  
 
Collecting duct carcinomas are derived from the medulla (many are infiltrative and extension into 
the cortex is common). Although there are some overlapping features with papillary renal cell 
carcinoma, the location of medulla and the predominantly tubular configuration of the tumour 
suggest collecting duct differentiation. An origin from the collecting ducts is supported by atypical 
hyperplasia of the collecting duct epithelium adjacent to the neoplasm as well as 
immunohistochemical studies. The cells of collecting duct carcinoma react positively with antibodies 
to both high- and low-molecular-weight cytokeratins and epithelial membrane antigen [91–93]. 
Vimentin reactivity is usually negative or weakly positive. This immunohistochemistry is 
characteristic of distal tubular epithelium and differs from most other types of renal cell carcinoma.  
Conclusions   
An inherited or familial predisposition to develop kidney carcinoma represents less than 4% of all 
renal malignancies. However, hereditary renal cancer syndromes offer important opportunities for 
identification of sentinel mutations driving carcinogenesis and malignant transformation and 
understanding how cells acquire characteristics allowing immortalisation, evasion of apoptosis, 
growth in a low- oxygen environment, recruitment of growth and angiogenic factors, invasion of the 
basement membrane and ultimately distant spread. This knowledge is crucial in developing targeted 
therapeutic strategies in metastatic kidney carcinoma that is refractory to conventional chemotherapy. 
Moreover, for patients, the discovery of a genetic predisposition to cancer often leads to early 
screening of themselves and their families and thus to early detection of tumours, when treatment is 
most successful.  
 
There are four well defined hereditary types of kidney cancer: VHL, HPRC type 1, BHD and 
hereditary HLRCC or hereditary papillary renal carcinoma type 2 (HLRCC). The gene implicated in 
all of them is a tumour-suppressor gene, except in HPRC type 1, in which it is the protooncogene c-
met, and all these syndromes have an autosomal dominant fashion. Genetic abnormality implicated in 
VHL disease is the loss of chromosome 3 and the gene implicated is VHL. This tumour-suppressor 
gene interacts with HIF and this activates its effectors, including those involved in cell proliferation 
(TGFα , VEGF, PDGF β ) and metabolism (Glut1), which have an important role in carcinogenesis. 
In HPRC type 1, missense mutation in the tyrosine kinase do- main of the met gene (chromosome 7q) 
leads to constitutive activation of the met protein and this initiates multiple signal transduction 
cascades that may be carcinogenic. The FH (chromosome 1q), a Krebs cycle protein, is implicated in 
hereditary HLRCC. If its activity is lost, fumarate accumulation may cause HIF overexpression and 
carcinogenesis. Although every syndrome is associated with the gene- sis of kidney cancer, the types 
of renal cancers, histologic features, genes causing the defects, location, clinical course and response 
to therapy differ between them. In this way, almost half of people with VHL develop a kidney clear 
cell carcinoma which is characterised as being multiple, bilateral, arising from the proximal tubular 
epithelium, containing cells rich in glycogen, appearing at a young age and having a high penetrance 
(80–90%). Disease "expressivity" or severity can be highly variable with other manifestations such as 
cerebellar and spinal haemangioblastomas, retinal angiomas, endolymphatic sac tumours, pancreatic 
neuroendocrine tumours, pheochromocytoma and renal, pancreatic and epididymal cysts. HPRC type 
1 is usually a bilateral, multifocal carcinoma that affects proximal tubule. It appears in old people, 
with a low penetrance, and exhibits abundant lipid-laden macrophages. In contrast, hereditary 
HLRCC is associated with a solitary, extremely aggressive carcinoma which appears in 25% of the 
people that inherit the syndrome and may develop much earlier in life, as early as the teenage years. It 
tends to spread early when the tumours are small, so it causes an important mortality. Affected 
individuals develop extra-renal manifestations such as multiple cutaneous leiomyomatosis and 
uterine leiomyomas that usually occur before 35 years. Individuals affected by BHD syndrome are at 
risk of the development not only of kidney carcinoma but also cutaneous fibrofolliculomas, 
pulmonary cysts and renal spontaneous pneumothorax. This histological type initiates in Bellini’s 
duct, in the medullary collecting tubule, and is commonly observed as an atypical hyperplasia of the 
adjacent collecting duct epithelium. Finally, between 15 and 30% of people with BHD syndrome 
develop kidney carcinoma: 50% oncocytic-transition carcinoma, 34% chromophobe renal carcinoma 
and 5% oncocytoma, which are un- common histological types in sporadic carcinoma (less than 
15%). 
 
In conclusion, although these inherited diseases currently account for only a minority of renal 
cancers, the lessons learned from them (gene functions and biochemical pathways) will have 
profound implications for the treatment of all forms of renal cancer.  
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